rAAV.sFlt-1 gene therapy achieves lasting reversal of retinal neovascularization in the absence of a strong immune response to the viral vector

Investigative Ophthalmology and Visual Science

Volumn 50, Issue 9, 2009, Pages 4279-4287

  Lai, Chooi May ^a,b   Estcourt, Marie J ^a,b   Wikstrom, Matthew ^a,b   Himbeck, Robyn P ^a,b   Barnett, Nigel L ^c   Brankov, Meliha ^a,b   Tee, Lisa B G ^d,e   Dunlop, Sarah A ^d,f   Degli Esposti, Mariapia A ^a,b   Rakoczy, Elizabeth P ^a,b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b LIONS EYE INSTITUTE   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^e CURTIN UNIVERSITY   (Australia)

^f UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CD45 ANTIGEN; PARVOVIRUS VECTOR; PHOSPHATE BUFFERED SALINE; VASCULOTROPIN RECEPTOR 1; FLT1 PROTEIN, MOUSE; VASCULAR ENDOTHELIAL GROWTH FACTOR A, MOUSE; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; GENE THERAPY; IMMUNE RESPONSE; LEUKOCYTE; MORPHOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RETINA CAPILLARY; RETINA FLUORESCEIN ANGIOGRAPHY; RETINA NEOVASCULARIZATION; TRANSGENIC MOUSE; UPREGULATION; VIRAL GENE DELIVERY SYSTEM; ADENO ASSOCIATED VIRUS; ANIMAL; ANTIBODY PRODUCTION; B LYMPHOCYTE; C57BL MOUSE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; DISEASE MODEL; ELECTRORETINOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FLUORESCENCE ANGIOGRAPHY; FLUORESCENT ANTIBODY TECHNIQUE; GENE VECTOR; GENETICS; IMMUNOLOGY; METABOLISM; PATHOLOGY; RETINA BLOOD VESSEL;

ANIMALS; ANTIBODY FORMATION; B-LYMPHOCYTES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; ELECTRORETINOGRAPHY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FLUORESCEIN ANGIOGRAPHY; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GENE THERAPY; GENETIC VECTORS; IMMUNITY, CELLULAR; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MICROSCOPY, CONFOCAL; RETINAL NEOVASCULARIZATION; RETINAL VESSELS; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 70349230977     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.08-3253     Document Type: Article

References (78)

1. Marshall E. Gene therapy death prompts review of adenovirus vector. Science. 1999;286(5448):2244-2245.
2. Check E. Regulators split on gene therapy as patient shows signs of cancer. Nature. 2002;419(6907):545-546.
3. Williams DA, Baum C. Gene therapy: new challenges ahead. Science. 2003;302(5644):400-401.
4. Kay MA, Manno CS, Ragni MV, et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet. 2000;24(3):257-261.
5. Manno CS, Arruda VR, Pierce GF, et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med. 2006;12(3):342-347.
6. Manno CS, Chew AJ, Hutchison S, et al. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood. 2003;101(8):2963-2972.
7. McPhee SW, Janson CG, Li C, et al. Immune responses to AAV in a phase I study for Canavan disease. J Gene Med. 2006;8(5):577-588.
8. Retracing events (no authors listed). Nat Biotechnol. 2007;25(9): 949.
9. Williams DA. RAC reviews serious adverse event associated with AAV therapy trial. Mol Ther. 2007;15(12):2053-2054.
10. Bainbridge JW, Smith AJ, Barker SS, et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med. 2008;358(21):2231-2239.
11. Maguire AM, Simonelli F, Pierce EA, et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med. 2008;358(21):2240-2248.
12. Cideciyan AV, Aleman TS, Boye SL, et al. Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. Proc Natl Acad Sci USA. 2008; 105(39):15112-15117.
13. Berns KI. Parvovirus replication. Microbiol Rev. 1990;54(3):316-329.
14. Berns KI, Linden RM. The cryptic life style of adeno-associated virus. Bioessays. 1995;17(3):237-245.
15. McCown TJ, Xiao X, Li J, Breese GR, Samulski RJ. Differential and persistent expression patterns of CNS gene transfer by an adenoassociated virus (AAV) vector. Brain Res. 1996;713(1-2):99-107.
16. Xiao X, Li J, Samulski RJ. Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J Virol. 1996;70(11):8098-8108.
17. During MJ, Xu R, Young D, et al. Peroral gene therapy of lactose intolerance using an adeno-associated virus vector. Nat Med. 1998; 4(10):1131-1135.
18. Leaver SG, Cui Q, Plant GW, et al. AAV-mediated expression of CNTF promotes long-term survival and regeneration of adult rat retinal ganglion cells. Gene Ther. 2006;13(18):1328-1341.
19. Lai CM, Shen WY, Brankov M, et al. Long-term evaluation of AAV-mediated sFlt-1 gene therapy for ocular neovascularization in mice and monkeys. Mol Ther. 2005;12(4):659-668.
20. Gao G, Lebherz C, Weiner DJ, et al. Erythropoietin gene therapy leads to autoimmune anemia in macaques. Blood. 2004;103(9): 3300-3302.
21. Denti MA, Rosa A, D'Antona G, et al. Body-wide gene therapy of Duchenne muscular dystrophy in the mdx mouse model. Proc Natl Acad Sci USA. 2006;103(10):3758-3763.
22. Wang L, Takabe K, Bidlingmaier SM, Ill CR, Verma IM. Sustained correction of bleeding disorder in hemophilia B mice by gene therapy. Proc Natl Acad Sci USA. 1999;96(7):3906-3910.
23. Mount JD, Herzog RW, Tillson DM, et al. Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy. Blood. 2002;99(8):2670-2676.
24. Snyder RO, Miao C, Meuse L, et al. Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors. Nat Med. 1999;5(1):64 -70.
25. Nathwani AC, Davidoff AM, Hanawa H, et al. Sustained high-level expression of human factor IX (hFIX) after liver-targeted delivery of recombinant adeno-associated virus encoding the hFIX gene in rhesus macaques. Blood. 2002;100(5):1662-1669.
26. Snyder RO, Miao CH, Patijn GA, et al. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nat Genet. 1997;16(3):270-276.
27. Nakai H, Herzog RW, Hagstrom JN, et al. Adeno-associated viral vector-mediated gene transfer of human blood coagulation factor IX into mouse liver. Blood. 1998;91(12):4600-4607.
28. Chirmule N, Xiao W, Truneh A, et al. Humoral immunity to adenoassociated virus type 2 vectors following administration to murine and nonhuman primate muscle. J Virol. 2000;74(5):2420-2425.
29. Clark KR, Sferra TJ, Johnson PR. Recombinant adeno-associated viral vectors mediate long-term transgene expression in muscle. Hum Gene Ther. 1997;8(6):659-669.
30. Fisher KJ, Jooss K, Alston J, et al. Recombinant adeno-associated virus for muscle directed gene therapy. Nat Med. 1997;3(3):306-312.
31. Lai YK, Shen WY, Brankov M, et al. Potential long-term inhibition of ocular neovascularisation by recombinant adeno-associated virus- mediated secretion gene therapy. Gene Ther. 2002;9(12):804-813.
32. Anand V, Chirmule N, Fersh M, Maguire AM, Bennett J. Additional transduction events after subretinal readministration of recombinant adeno-associated virus. Hum Gene Ther. 2000;11(3):449-457.
33. Xiao W, Chirmule N, Schnell MA, et al. Route of administration determines induction of T-cell-independent humoral responses to adeno-associated virus vectors. Mol Ther. 2000;1(4):323-329.
34. Vandenberghe LH, Wang L, Somanathan S, et al. Heparin binding directs activation of T cells against adeno-associated virus serotype 2 capsid. Nat Med. 2006;12(8):967-971.
35. Brockstedt DG, Podsakoff GM, Fong L, et al. Induction of immunity to antigens expressed by recombinant adeno-associated virus depends on the route of administration. Clin Immunol. 1999;92(1): 67-75.
36. Ge Y, Powell S, Van Roey, MMcArthur JG. Factors influencing the development of an anti-factor IX (FIX) immune response following administration of adeno-associated virus-FIX. Blood. 2001;97(12): 3733-3737.
37. Gross DA, Leboeuf M, Gjata B, Danos ODavoust J. CD4+ CD25+ regulatory T cells inhibit immune-mediated transgene rejection. Blood. 2003;102(13):4326-4328.
38. Chenuaud P, Larcher T, Rabinowitz JE, et al. Autoimmune anemia in macaques following erythropoietin gene therapy. Blood. 2004; 103(9):3303-3304.
39. Cordier L, Gao GP, Hack AA, et al. Muscle-specific promoters may be necessary for adeno-associated virus-mediated gene transfer in the treatment of muscular dystrophies. Hum Gene Ther. 2001; 12(2):205-215.
40. Halbert CL, Standaert TA, Aitken ML, et al. Transduction by adenoassociated virus vectors in the rabbit airway: efficiency, persistence, and readministration. J Virol. 1997;71(8):5932-5941.
41. Halbert CL, Standaert TA, Wilson CB, Miller AD. Successful readministration of adeno-associated virus vectors to the mouse lung requires transient immunosuppression during the initial exposure. J Virol. 1998;72(12):9795-9805.
42. Xiao W, Chirmule N, Berta SC, et al. Gene therapy vectors based on adeno-associated virus type 1. J Virol. 1999;73(5):3994-4003.
43. Lai CM, Dunlop SA, May LA, et al. Generation of transgenic mice with mild and severe retinal neovascularisation. Br J Ophthalmol. 2005;89(7):911-916.
44. Shen WY, Lai CM, Graham CE, et al. Long-term global retinal microvascular changes in a transgenic vascular endothelial growth factor mouse model. Diabetologia. 2006;49(7):1690-1701.
45. van Eeden PE, Tee LB, Lukehurst S, et al. Early vascular and neuronal changes in a VEGF transgenic mouse model of retinalneovascularization. Invest Ophthalmol Vis Sci. 2006;47(10):4638-4645.
46. Shen WY, Lai CM, Lai YK, et al. Practical considerations of recombinant adeno-associated virus-mediated gene transfer for treatment of retinal degenerations. J Gene Med. 2003;5(7):576-587.
47. Holcombe DJ, Lengefeld N, Gole GA, Barnett NL. Selective inner retinal dysfunction precedes ganglion cell loss in a mouse glaucoma model. Br J Ophthalmol. 2008;92(5):683-688.
48. Hood DC, Birch DG. A quantitative measure of the electrical activity of human rod photoreceptors using electroretinography. Vis Neurosci. 1990;5(4):379-387.
49. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351(27):2805-2816.
50. Presta LG, Chen H, O'Connor SJ, et al. Humanization of an antivascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997; 57(20):4593- 4599.
51. Oshima Y, Sakaguchi H, Gomi F, Tano Y. Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy. Am J Ophthalmol. 2006;142(1):155-158.
52. Spaide RF, Fisher YL. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina. 2006;26(3):275-278.
53. Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology. 2006;113(10):1695 e1691-1615.
54. Friedlander SM, Welch RM. Vanishing disc neovascularization following intravitreal bevacizumab (avastin) injection. Arch Ophthalmol. 2006;124(9):1365.
55. Rich RM, Rosenfeld PJ, Puliafito CA, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular agerelated macular degeneration. Retina. 2006;26(5):495-511.
56. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging. 2005;36(4):331-335.
57. Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006;113(3):363-372 e365.
58. Heier JS, Antoszyk AN, Pavan PR, et al. Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. Ophthalmology. 2006; 113(4):642 e641-644.
59. Thomas KA. Vascular endothelial growth factor, a potent and selective angiogenic agent. J Biol Chem. 1996;271(2):603-606.
60. Kendall RL, Thomas KA. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA. 1993;90(22):10705-10709.
61. Kendall RL, Wang G, Thomas KA. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem Biophys Res Commun. 1996;226(2):324-328.
62. Ambati BK, Nozaki M, Singh N, et al. Corneal avascularity is due to soluble VEGF receptor-1. Nature. 2006;443(7114):993-997.
63. Kong HL, Hecht D, Song W, et al. Regional suppression of tumor growth by in vivo transfer of a cDNA encoding a secreted form of the extracellular domain of the flt-1 vascular endothelial growth factor receptor. Hum Gene Ther. 1998;9(6):823- 833.
64. Mahendra G, Kumar S, Isayeva T, et al. Antiangiogenic cancer gene therapy by adeno-associated virus 2-mediated stable expression of the soluble FMS-like tyrosine kinase-1 receptor. Cancer Gene Ther. 2005;12(1):26 -34.
65. Mahasreshti PJ, Navarro JG, Kataram M, et al. Adenovirus-mediated soluble FLT-1 gene therapy for ovarian carcinoma. Clin Cancer Res. 2001;7(7):2057-2066.
66. Hasumi Y, Mizukami H, Urabe M, et al. Soluble FLT-1 expression suppresses carcinomatous ascites in nude mice bearing ovarian cancer. Cancer Res. 2002;62(7):2019-2023.
67. Afuwape AO, Feldmann M, Paleolog EM. Adenoviral delivery of soluble VEGF receptor 1 (sFlt-1) abrogates disease activity in murine collagen-induced arthritis. Gene Ther. 2003;10(23):1950-1960.
68. Gehlbach P, Demetriades AM, Yamamoto S, et al. Periocular gene transfer of sFlt-1 suppresses ocular neovascularization and vascular endothelial growth factor-induced breakdown of the blood-retinal barrier. Hum Gene Ther. 2003;14(2):129 -141.
69. Rota R, Riccioni T, Zaccarini M, et al. Marked inhibition of retinal neovascularization in rats following soluble-flt-1 gene transfer. J Gene Med. 2004;6(9):992-1002.
70. Lai CM, Brankov M, Zaknich T, et al. Inhibition of angiogenesis by adenovirus-mediated sFlt-1 expression in a rat model of corneal neovascularization. Hum Gene Ther. 2001;12(10): 1299 -1310.
71. Bainbridge JW, Mistry A, De Alwis M, et al. Inhibition of retinal neovascularisation by gene transfer of soluble VEGF receptor sFlt-1. Gene Ther. 2002;9(5):320 -326.
72. Detmar M, Brown LF, Schon MP, et al. Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice. J Invest Dermatol. 1998;111(1): 1- 6.
73. Lu M, Perez VL, Ma N, et al. VEGF increases retinal vascular ICAM-1 expression in vivo. Invest Ophthalmol Vis Sci. 1999;40(8):1808-1812.
74. Miyamoto K, Khosrof S, Bursell SE, et al. Vascular endothelial growth factor (VEGF)-induced retinal vascular permeability is mediated mediated by intercellular adhesion molecule-1 (ICAM-1). Am J Pathol. 2000;156(5):1733-1739.
75. Tolentino MJ, Miller JW, Gragoudas ES, et al. Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate. Arch Ophthalmol. 1996;114(8):964 -970.
76. Li Q, Miller R, Han PY, et al. Intraocular route of AAV2 vector administration defines humoral immune response and therapeutic potential. Mol Vis. 2008;14:1760-1769.
77. Carter BJ, Flotte TR. Development of adeno-associated virus vectors for gene therapy of cystic fibrosis. Curr Top Microbiol Immunol. 1996;218(119-144).
78. Russell DW, Kay MA. Adeno-associated virus vectors and hematology. Blood. 1999;94(3):864-874.